# Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

> **NCT02051764** · PHASE2 · TERMINATED · sponsor: **Avid Radiopharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Flortaucipir F18
- **DRUG:** Florbetapir F 18
- **PROCEDURE:** Brain PET Scan

## Key facts

- **NCT ID:** NCT02051764
- **Lead sponsor:** Avid Radiopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Lower than expected enrollment
- **Last updated:** 2020-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051764, "Imaging Characteristics of a Follow-up 18F-AV-1451 Scan". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02051764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*